Now approved

AMVUTTRA™ (vutrisiran) is a prescription medicine given once every 3 months by a healthcare professional to treat the polyneuropathy caused by an illness called hereditary ATTR (hATTR) amyloidosis in adults.

In an 18-month clinical study, AMVUTTRA-treated patients showed significant improvement in nerve function and quality of life at 9 months and continued to improve throughout the study, compared with those who received placebo in a similar study.

  • aNerve function was assessed using a scale called mNIS+7 that measured strength and sensation in the hands, feet, arms, and legs; reflexes; and blood pressure upon standing.
  • bQuality of life was evaluated by the Norfolk QoL-DN questionnaire that asked patients about the severity of their polyneuropathy symptoms, how often they experienced them, and what impact they felt they had on their daily lives.

Stay informed

Receive the latest information about AMVUTTRA, answers to commonly asked questions, and patient and caregiver resources to help you learn more about the disease.
All fields are required.

Get personalized support through Alnylam Assist™

Alnylam Assist is a patient support program designed to help you get started on treatment, understand your insurance coverage, discuss financial assistance options you may be eligible for, and provide you with ongoing support in your treatment journey.

Monday–Friday, 8 AM–6 PM ET
To learn more, visit www.AlnylamAssist.com
  • Patient Assistance Program (PAP) provides AMVUTTRA at no cost to eligible patients, primarily the uninsured, who meet specified financial criteria
  • Commercial Copay Programb covers certain out-of-pocket costs for eligible patients with commercial insurance
  • aPatients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.
  • bPatients with Medicare, Medicaid, or other government-sponsored insurance are not eligible for the Alnylam Assist™ Commercial Copay Program. Out-of-pocket costs for the administration of AMVUTTRA will not be covered for patients residing where it is prohibited by law or where otherwise restricted.

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about AMVUTTRA™ (vutrisiran)?

AMVUTTRA can cause:

  • Low Vitamin A Levels

    Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist.

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about AMVUTTRA™ (vutrisiran)?

AMVUTTRA can cause:

  • Low Vitamin A Levels

    Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist

Important Safety Information and Indication

Important Safety Information

What are the most important things I should know about AMVUTTRA™ (vutrisiran)?

AMVUTTRA can cause:

  • Low Vitamin A Levels

    Treatment with AMVUTTRA lowers the amount of vitamin A in your blood. Your doctor will tell you to take a vitamin A supplement every day. You should not take more than the amount of vitamin A recommended by your doctor.

    Low vitamin A levels can affect vision. If you have problems with your vision (e.g., night blindness) while taking AMVUTTRA, talk to your doctor. Your doctor may refer you to an eye specialist

What are the common side effects of AMVUTTRA?

The most common side effects of AMVUTTRA are pain in the joints (arthralgia), shortness of breath (dyspnea), and low vitamin A levels.

These are not all the possible side effects of AMVUTTRA. Talk to your doctor about side effects that you experience. You are encouraged to report negative side effects of prescription drugs to the U.S. Food and Drug Administration (FDA). Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indication

What is AMVUTTRA?

AMVUTTRA is a prescription medicine that treats the polyneuropathy caused by an illness called hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). AMVUTTRA is used in adults only.

For additional information about AMVUTTRA, please see the full Prescribing Information.